Breast Cancer
Conditions
Keywords
Breast Cancer, Oncotype DX, Adjuvant! Online, Decisional Conflict Scale
Brief summary
A prospective population-based cohort study is being conducted in Ontario to evaluate whether the performance of Oncotype DX® changes the treatment recommended and the treatment received in women or men with node negative, ER positive breast cancer who are receiving (or will receive) endocrine therapy and who are candidates for chemotherapy. One thousand eligible consenting women and men will have their tumor tissue specimen sent to Genomic Health where the Oncotype DX® assay will be performed.
Detailed description
The evidence supporting the adoption of Oncotype DX® is relatively weak by the criteria used by the Ontario Health Technology Advisory Committee (OHTAC). There is only one small published prospective study that reports on Oncotype DX® changing clinical management. The economic models that estimated the potential advantages of using an Oncotype DX® guided treatment strategy may have overestimated the benefits because they assumed that all patients with tumors \>1cm in the absence of Oncotype DX® testing would receive chemotherapy in addition to tamoxifen, and that the magnitude of benefit with chemotherapy over tamoxifen is relatively large, i.e. reduces recurrence risk by 74% and associated with an absolute benefit of 28%. (The benefit comes from one trial and is applied to all patients). It is estimated that there are about 3,300 incident cases with node negative, ER positive, HER2 neu negative tumors annually in Ontario, it is important to evaluate the adoption of this test for decision making in Ontario.
Interventions
GENETICONCOTYPEDX Test
Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
Sponsors
Ontario Ministry of Health and Long Term Care
Ontario Clinical Oncology Group (OCOG)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women or men with histologic evidence of invasive breast cancer (ductal, lobular or mixed disease). * Surgical resection including breast conserving surgery or modified radical mastectomy or simple mastectomy, within the last four months. * Axillary lymph nodes assessed for tumor by: (i) sentinel node biopsy, or (ii) axillary node dissection, or (iii) both * Axillary lymph node assessment negative for cancer, or positive only for micrometastases (i.e., cancer \<2mm by H&E stain). * Tumor is estrogen receptor (ER) positive. * Receiving or to receive adjuvant endocrine therapy (i.e., tamoxifen or aromatase inhibitor). * Being considered for adjuvant chemotherapy.
Exclusion criteria
* Axillary lymph node positive for cancer. * Patients with inoperable locally advanced breast cancer. * Metastatic breast cancer, including local ipsilateral recurrence. * HER2 neu positive. * Physician/Patient unwilling to comply with study protocol. * Inability to provide informed consent (e.g. dementia or severe cognitive impairment).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in treatment recommendation | One month | The primary outcome is the change in treatment recommendation by the oncologist and the change in treatment preference of the patient. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Association between Oncotype DX® RS with other estimated risk calculations | One month | The level of association between the Oncotype DX® RS with estimated recurrence risk calculated by Adjuvant! Online, as well as with traditional factors including tumor size, grade, and HER2 neu. |
| Change in patient decisional conflict | One month | The change in the level of patient decisional conflict measured by the Decisional Conflict Scale (DCS). Additionally, the DCS has three subscales: uncertainty, effective decision making, and factors contributing to uncertainty. The change in each of these subscales will also be measured. |
| Robustness of economic model of sequential Adjuvant! Online followed by Oncotype DX®. | 6 months | To determine the robustness of the economic model of sequential Adjuvant! Online followed by Oncotype DX®. |
Countries
Canada
Outcome results
None listed